| Market Cap | ₹5,244.12 CrMid-range Performer |
|---|---|
| P/E TTM | 39.29xSector PE 48.58x |
| Revenue TTM | ₹722.29 CrOperating Income |
| 1-Year Return | 45.91%Price Performance |
Key highlights
- Certification issued by Ukraine State Service on Medicines and Drugs Control on November 16, 2026
- Awarded under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) framework
- Facility located at Mehsana, Gujarat owned by subsidiary Ratnatris Pharmaceuticals
- Opens regulatory pathways across semi-regulated markets for the company's products
- Official receipt of the GMP compliance certificate confirmed on November 17, 2026
Certification Details and Market Access
Senores Pharmaceuticals disclosed that its subsidiary, Ratnatris Pharmaceuticals Private Limited, achieved a significant regulatory milestone with the receipt of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacturing Practices (GMP) certification. The certificate was issued by the State Service of Ukraine on Medicines and Drugs Control (SMDC) specifically for the Mehsana, Gujarat facility. This regulatory approval serves as a gateway for the company to pursue product registrations and commercial operations across a broader range of semi-regulated markets, leveraging the international standards recognized under the PIC/S framework.
Strategic Development and Pipeline Milestones
- The company maintains an active formulation development pipeline of 41 molecules covering 130 strengths
- A total of 41 approved Abbreviated New Drug Applications (ANDAs) across 153 strengths are scheduled for launch
- Management expects 3 to 4 new ANDA approvals and 12 to 15 sANDA approvals from the USFDA during Q3 FY27
- Ongoing capacity expansion worth 43 crore across Havix, Apnar, and Ratnatris is scheduled for March 2027 completion
- Consolidated revenue growth guidance for FY27 is maintained at 30% to 40% with PAT growth targeted at 50% to 60%
Financial Performance Context
For the quarter ended September 30, 2026, Senores Pharmaceuticals reported a consolidated operating revenue of 192.33 crore, representing an 18.9 percent growth over the same period last year. Net profit for the same quarter stood at 39.49 crore, up 22.0 percent year-on-year, with an operating profit margin of 29.98 percent. The company's annual figures show a robust revenue growth of 62.8 percent and a net profit increase of 97.0 percent for the full year.
With a current price-to-earnings ratio of 39.29, the stock is trading below the industry average of 43.54.
What to watch next
- Completion of the 43 crore capacity expansion project by March 2027
- USFDA decisions on 3 to 4 new ANDA approvals expected during Q3 FY27
- Launch timeline for 41 approved ANDAs covering 153 strengths
- Finalization of FY27 financial results to meet guidance of 50-60% PAT growth
| Share price | ₹1138.7 |
|---|---|
| Market capitalisation | ₹5,244.12 Cr |
| Revenue (annual) | ₹632.63 Cr |
| Net profit (annual) | ₹115.37 Cr |
| Revenue (latest quarter) | ₹192.33 Cr+6.73% vs previous quarter |
| Net profit (latest quarter) | ₹39.49 Cr+28.55% vs previous quarter |
| P/E (TTM) | 39.29×Sector 48.58× |
| Promoter holding | 45.82%0.00% QoQ |
| FII holding | 6.01%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Senores Pharmaceuticals Limited announcing the issuance of a Certificate of GMP Compliance by the State Service of Ukraine on Medicines and Drugs Control. Market figures from a third-party data provider.




